RE:RE:RE:RE:RE:RE:RE:RE:RE:Using the ATM or HC44 - IMHO, we won't get any stock price appreciation until ONC takes these great study results and turns them in to great (transformational) business results - either a buyout or a solid partnership deal for Phase III programs. The market seems to be tired of hearing wonderful study stats without seeing management capitalize on them and turn them into something that would push the business forward. As a result, we only see lifers (myself included) or short-term traders who buy for the run-up then sell within days (I have been in this camp too).
ONC management has to give the market a solid business reason to move the stock price to a new (higher) normal. Yet another Phase II trial or even great results in existing trials will not do this.